160 related articles for article (PubMed ID: 18942400)
1. [Role of hormonal profile in adjusting therapy for prostate cancer].
Granov AM; Molchanov OE; Karelin MI
Vopr Onkol; 2008; 54(4):457-62. PubMed ID: 18942400
[TBL] [Abstract][Full Text] [Related]
2. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy.
Bruchovsky N; Klotz L; Crook J; Goldenberg SL
Cancer; 2007 Mar; 109(5):858-67. PubMed ID: 17265527
[TBL] [Abstract][Full Text] [Related]
3. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.
Yoon FH; Gardner SL; Danjoux C; Morton G; Cheung P; Choo R
J Urol; 2008 Oct; 180(4):1438-43; discussion 1443-4. PubMed ID: 18710743
[TBL] [Abstract][Full Text] [Related]
4. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation.
Salonen AJ; Viitanen J; Lundstedt S; Ala-Opas M; Taari K; Tammela TL;
J Urol; 2008 Sep; 180(3):915-9; discussion 919-20. PubMed ID: 18635219
[TBL] [Abstract][Full Text] [Related]
5. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
[TBL] [Abstract][Full Text] [Related]
6. How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients?
Choo R; Chander S; Danjoux C; Morton G; Pearce A; Deboer G; Szumacher E; Loblaw A; Cheung P; Woo T
Can J Urol; 2005 Feb; 12(1):2547-52. PubMed ID: 15777493
[TBL] [Abstract][Full Text] [Related]
7. Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy.
Tunn UW; Canepa G; Kochanowsky A; Kienle E
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):296-302. PubMed ID: 22733160
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
9. Equivalent and sufficient effects of leuprolide acetate and goserelin acetate to suppress serum testosterone levels in patients with prostate cancer.
Fujii Y; Yonese J; Kawakami S; Yamamoto S; Okubo Y; Fukui I
BJU Int; 2008 May; 101(9):1096-100. PubMed ID: 18190637
[TBL] [Abstract][Full Text] [Related]
10. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy.
Taira AV; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1143-9. PubMed ID: 19117691
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment hormone levels in prostatic cancer.
Haapiainen R; Rannikko S; Alfthan O; Adlercreutz H
Scand J Urol Nephrol Suppl; 1988; 110():137-43. PubMed ID: 3187401
[TBL] [Abstract][Full Text] [Related]
13. Managing prostate cancer: the role of hormone therapy.
Ramirez ML; Keane TE; Evans CP
Can J Urol; 2007 Dec; 14 Suppl 1():10-8. PubMed ID: 18163939
[TBL] [Abstract][Full Text] [Related]
14. [Plasma testosterone: a sound criterion of the effectiveness of hormonal treatment of prostatic carcinoma].
Maleeva A; Tsvetkov M; Kekhaĭova M
Vutr Boles; 1980; 19(3):42-6. PubMed ID: 6771918
[TBL] [Abstract][Full Text] [Related]
15. [Time-course of plasma testosterone in patients with prostate cancer treated by endocrine therapy].
Peyromaure M; Rebillard X; Ruffion A; Salomon L; Villers A; Soulie M;
Prog Urol; 2008 Jan; 18(1):2-8. PubMed ID: 18342148
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study.
Spry NA; Galvão DA; Davies R; La Bianca S; Joseph D; Davidson A; Prince R
BJU Int; 2009 Sep; 104(6):806-12. PubMed ID: 19281463
[TBL] [Abstract][Full Text] [Related]
17. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
18. Current status and prospects of androgen depletion therapy for prostate cancer.
Akaza H
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):293-302. PubMed ID: 18471787
[TBL] [Abstract][Full Text] [Related]
19. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment: a case report].
Matsumoto Y; Mibu H; Kagebayashi Y
Hinyokika Kiyo; 2004 Nov; 50(11):813-5. PubMed ID: 15628545
[TBL] [Abstract][Full Text] [Related]
20. [Aminoglutethimide in the treatment of advanced prostatic cancer].
Bauer HW; Schmeller NT; Schmiedt E
Urologe A; 1985 Jan; 24(1):46-8. PubMed ID: 4039084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
